Reference health
Integrating Nanotechnology into Cancer Care
52/52 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
8 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 52 checked references that resolve
resolves10.2217/nnm.13.191
Shaping Cancer Nanomedicine: The Effect of Particle Shape on The
<i>In Vivo</i>
Journey of Nanoparticles
resolves10.1039/C8NR04042G
Influence of particle size and shape on their margination and wall-adhesion: implications in drug delivery vehicle design across nano-to-micro scale
resolves10.1021/acsnano.7b07878
Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer
resolves10.1016/j.addr.2016.01.007
Impact of particle elasticity on particle-based drug delivery systems
resolves10.1016/j.biomaterials.2013.07.049
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics
resolves10.1038/nmat2992
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers
resolves10.1021/ar200028a
Nanoscale Metal–Organic Frameworks for Biomedical Imaging and Drug Delivery
resolves10.1038/s41467-018-04703-w
Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy
resolves10.1158/0008-5472.CAN-12-4561
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
resolves10.1021/acsnano.6b08244
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions
resolves10.1158/1078-0432.CCR-16-3193
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
resolves10.1073/pnas.85.18.6949
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
resolves10.1021/acsnano.6b05935
Exploiting the Metal-Chelating Properties of the Drug Cargo for <i>In Vivo</i> Positron Emission Tomography Imaging of Liposomal Nanomedicines
resolves10.1001/jamaoncol.2018.2168
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
resolves10.1186/s12885-016-2385-z
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
resolves10.1021/acs.nanolett.7b01171
Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers
resolves10.1016/j.cell.2015.03.037
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
resolves10.1038/ncomms13050
Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers
resolves10.1038/ncomms9692
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
resolves10.1016/j.jconrel.2017.12.023
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate
resolves10.1016/j.molmed.2018.03.006
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
resolves10.1038/nature21409
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
resolves10.1016/j.molimm.2014.06.038
Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals
resolves10.1001/archderm.136.12.1475
Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin
resolves10.1016/j.jconrel.2016.02.011
Cellular biodistribution of polymeric nanoparticles in the immune system
resolves10.3389/fimmu.2017.00590
Nanoparticle-Based Magnetic Resonance Imaging on Tumor-Associated Macrophages and Inflammation
resolves10.1021/acsnano.8b04338
Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using <sup>64</sup>Cu-Labeled Macrin
resolves10.1021/acsnano.7b07252
Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics
resolves10.1056/NEJMoa022749
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
resolves10.1002/wnan.1380
Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle
resolves10.7150/thno.16514
Near Infrared Fluorescent Nanoparticles Derived from Hyaluronic Acid Improve Tumor Contrast for Image-Guided Surgery
resolves10.1158/1078-0432.CCR-12-3598
Optical Image-Guided Cancer Surgery: Challenges and Limitations
resolves10.1038/ncomms7570
Rational design of a chalcogenopyrylium-based surface-enhanced resonance Raman scattering nanoprobe with attomolar sensitivity
resolves10.1126/scitranslmed.3010633
Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging
resolves10.1038/nm.2721
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle
resolves10.7150/thno.18019
Chelator-Free Radiolabeling of SERRS Nanoparticles for Whole-Body PET and Intraoperative Raman Imaging
resolves10.7150/ntno.25565
Multifunctional Magnetic Mesoporous Silica Nanoagents for <i>in vivo</i> Enzyme-Responsive Drug Delivery and MR Imaging
resolves10.1016/j.xphs.2017.06.019
Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection
resolves10.1126/scitranslmed.aac6522
Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle
resolves10.1016/j.addr.2016.04.025
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
resolves10.1016/j.jconrel.2016.04.028
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
The 8 references without a DOI — listed, not checked
no DOI — not checkedref13/cit13
no DOI — not checkedLIQ861 for Pulmonary
Arterial Hypertension (PAH). http://liquidia.com/pipeline/liq861/ (Accessed June 17, 2019).
no DOI — not checkedHouston Methodist –
GMP facilities. https://www.houstonmethodist.org/research/our-research/cores/translational-production-quality/cgmp-core-quality-control-laboratories/ (Accessed June 17, 2019).
no DOI — not checkedRiMO – pipeline. http://www.rimorx.com/pipeline/ (Accessed June 17, 2019).
no DOI — not checkedref23/cit23
no DOI — not checkedref28/cit28
no DOI — not checkedref43/cit43
no DOI — not checkedAlnylam Announces First-Ever FDA Approval
of an RNAi Therapeutic. http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-first-ever-fda-approval-rnai-therapeutic (Accessed June 17, 2019).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1021/acsnano.9b04266"><img src="https://citestamp.com/citestamped/10.1021/acsnano.9b04266/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1021/acsnano.9b04266)